Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer

Abstract

BackgroundTo evaluate the efficacy and tolerability of capecitabine combined with thalidomide in patients with advanced pancreatic cancer (APC) who have previously received gemcitabine-based therapy. MethodsA total of 31 patients were recruited prospectively in Shandong Tumor Hospital from May 2007 to April 2009. Capecitabine was offered to patients twice a day at a dose of 1250 mg/m2 for 14-day then followed by 7-day rest. Thalidomide was administered 100 mg/day without interruption until disease progression or occurrence of unacceptable toxicity. ResultsTwo patients presented partial response (PR), 11 patients showed stable disease (SD) and eighteen patients presented progressive disease (PD). The median progression-free survival (PFS) was 2.7 months (95% confidence interval (CI), 2.4–3.3) and the median overall survival (OS) was 6.1 months (95% CI, 5.3–6.9). In the subgroup analysis, PFS had a significant difference between the serum CA19–9 level decreasing >25% and decreasing <25%, with 3.0 months (95% CI, 2.5–3.6) and 2.5 months (95% CI, 1.8–3.2), (Log Rank = 0.02), respectively. Hematological toxicity included leukocytopenia, anemia and neutropenia. Non-hematological toxicities included diarrhea, skin rash, nausea/vomiting, hand-foot syndrome, fatigue, dizziness, drowsiness and constipation. ConclusionCapecitabine combined with thalidomide is a well-tolerated second-line regimen, in patients with APC refractory to gemcitabine.